Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer SOMERSET, N.J.

Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer

SOMERSET, N.J., June 20, 2023 Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients

worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023.

Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was

acquired by Apollo. Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation.

finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Catalent reach its next level of performance, including enhanced profitability and

value-creation for shareholders, said Alessandro Maselli, President and Chief Executive Officer of Catalent. He brings significant expertise and a highly strategic approach that I am confident will make him an invaluable addition to

Catalent s executive leadership team as we continue to seize opportunities in the CDMO space.

Earlier in his career, Mr. Masanovich held

finance leadership roles of increasing responsibility in a number of companies in the automotive industry, where he demonstrated a strong history of improvement and profitability and operating efficiency. Mr. Masanovich began his career with

PricewaterhouseCoopers LLP. He has Bachelor of Commerce, Finance & Accounting and M.B.A. degrees from the University of Windsor and is a Chartered Accountant in Canada.

Catalent is a dynamic company that operates in a critical, fast-growing sector that has a meaningful impact on helping people live longer, healthier

lives. I am impressed with their portfolio of solutions and feel the company has the right capabilities to serve that market, and I am excited to work with Catalent s talented team to create value for its customers, patients, and

shareholders, said Mr. Masanovich.

Mr. Masanovich will have responsibility for all aspects of Catalent s global financial

operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury. He will also be a member of Catalent s executive

leadership team, the highest level of company management.

Catalent, Inc. (NYSE: CTLT), an S&P 500 company, is the global leader in enabling pharma,

biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality

manufacturing, Catalent is a preferred industry partner for personalized

medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing

platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New

Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All

statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management s current expectations. These statements are

neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from Catalent s expectations and projections

expressed or implied by the forward-looking statements. Important factors include, but are not limited to, those discussed under the caption Risk Factors in Catalent s Annual Report on Form

10-K for the year ended June 30, 2022 (as amended), Catalent s Quarterly Report on Form 10-Q for the three and nine months ended March 31, 2023, and

Catalent s other filings with the SEC. Forward-looking statements speak only as of the date of this press release and are based on information available to Catalent as of the date of this press release, and Catalent assumes no obligation to

update such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Paul Surdez, Catalent, Inc.